2015
DOI: 10.1586/14737140.2015.1071668
|View full text |Cite
|
Sign up to set email alerts
|

Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

Abstract: Lymphoplasmacytic lymphoma is an indolent B-cell, non-Hodgkin lymphoma (NHL), the majority of which are characterized by production of a monoclonal immunoglobulin M (IgM) protein and are known as Waldenström macroglobulinemia. Identification of highly recurrent activating somatic mutation in MYD88 has improved our understanding of the pathogenesis of Waldenström macroglobulinemia and has therapeutic implications. Here, we review novel therapeutic agents in Waldenström macroglobulinemia/lymphoplasmacytic lympho… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2016
2016
2020
2020

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 58 publications
0
2
0
Order By: Relevance
“…The chemotherapy regimen is cyclophosphamide + doxorubicin + vincristine + prednison (CHOP) or cyclophosphamide, vincristine, and prednisone, with rituximab—a monoclonal antibody widely used against B cell lymphoma. [19] Patients who received rituximab along with CHOP reportedly had significantly higher rates of overall response than patients who only received the traditional regimen.…”
Section: Discussionmentioning
confidence: 99%
“…The chemotherapy regimen is cyclophosphamide + doxorubicin + vincristine + prednison (CHOP) or cyclophosphamide, vincristine, and prednisone, with rituximab—a monoclonal antibody widely used against B cell lymphoma. [19] Patients who received rituximab along with CHOP reportedly had significantly higher rates of overall response than patients who only received the traditional regimen.…”
Section: Discussionmentioning
confidence: 99%
“…The mainstays of therapy are decreasing serum viscosity through IV fluid resuscitation, plasmapheresis, or leukopheresis 6367. Phlebotomy (e.g., polycythemia) or even urgent chemotherapy (e.g., acute leukemia) may also be indicated 6367. Evidence for these interventions suggests they do not alter the course of the disease but rather help with symptom alleviation.…”
Section: Hyperviscosity Syndromementioning
confidence: 99%